申请人:Ortho-McNeil Pharaceutical, Inc.
公开号:US06083969A1
公开(公告)日:2000-07-04
This invention is directed to certain 1,3- and 2,3-diarylpyrazole antiinflammatory compounds of the general formulae: ##STR1## wherein R.sub.1 and R.sub.2 are independently selected from the group consisting of hydrogen, halogen, (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, nitro, amino, hydroxy, trifluoro, --S(C.sub.1 -C.sub.6)alkyl, --SO(C.sub.1 -C.sub.6)alkyl and --SO.sub.2 (C.sub.1 -C.sub.6)alkyl and the fused moiety Q is a group selected from the group consisting of an optionally substituted cyclohexyl and cycloheptyl group as herein described, pharmaceutical compositions containing the compounds, processes for their production and use as COX-2 inhibitor and antiinflammatory agents.
这项发明涉及特定的1,3-和2,3-二芳基吡唑抗炎化合物,其一般式如下:##STR1##其中R.sub.1和R.sub.2分别独立地选自氢、卤素、(C.sub.1 -C.sub.6)烷基、(C.sub.1 -C.sub.6)氧烷基、硝基、氨基、羟基、三氟甲基、--S(C.sub.1 -C.sub.6)烷基、--SO(C.sub.1 -C.sub.6)烷基和--SO.sub.2(C.sub.1 -C.sub.6)烷基组成的群,以及融合基团Q是选自所述的可选择取代的环己基和环庚基群的一个群,含有这些化合物的药物组合物、其生产的过程以及作为COX-2抑制剂和抗炎药剂的用途。